
CSL Strikes Up to $1.6 Billion Deal with Alentis to Co-Develop Rare Disease Drug
CSL will pay Alentis $355 million upfront, with the Swiss biotech eligible for up to $1.2 billion more in commercial milestone payments tied to lixudebart, a potential first-in-class rare-disease treatment.
By: hammadkhaksar
